Roche Inks Pact To Acquire LumiraDx's Point of Care Technology

Roche announced the signing of a definitive agreement to buy certain components of the LumiraDx group relating to the revolutionary Point of Care technology developed by LumiraDx. The purchased firms will be fully integrated into Roche Diagnostics following the transaction's completion, which is scheduled in mid-2024.

“The addition of the LumiraDx technology to our diagnostics portfolio will enable us to transform testing at the point of care.” said Matt Sause, CEO Roche Diagnostics. “LumiraDx has developed a highly versatile platform that delivers strong performance across multiple disease areas and technologies. We believe this will enable better patient access to timely results in decentralised healthcare settings worldwide.”

Veronique Ameye, chief executive officer of LumiraDx added, “Since our founding, we have sought to transform community-based healthcare by consolidating multiple Point of Care tests on a single instrument. We are thrilled that Roche will continue this important work and increase its reach around the globe. This will enable more patients to get fast and easy access to better diagnostic testing.”

The transaction is part of Roche’s vision to enable more patient-centric healthcare, with Point of Care solutions that span the entire patient journey – from the home, pharmacy and general practitioner’s office to the emergency room, intensive care unit and beyond, as per pharmabiz. 

The purchased technology platform provides a wide range of immunoassay and clinical chemistry assays, with significant future potential for additional high medical value diagnostics. These may be maintained at room temperature, making them suitable for use in a variety of decentralized healthcare settings. Roche will be able to drive access to timely, accurate diagnostic results when and where patients need them most by using its large worldwide reach and established affiliate network.